Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ASKG712 · 2 trials · 2 indications
Any relevant ocular observations derived from best corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, ophthalmoscopy, optical coherence tomography (OCT), fundus photography, and angiography
Any clinical safety observations assessed by physical examination, vital signs, electrocardiograph (ECG) and clinical laboratory tests
Any changes of clinical safety observations assessed by vital signs, electrocardiograph (ECG), clinical laboratory tests and physical examination
| Arm | Type | Description |
|---|---|---|
| ASKG712 | EXPERIMENTAL | Multiple doses of ASKG712 by intravitreal injection |
| Name | Type | Description |
|---|---|---|
| ASKG712 | BIOLOGICAL | ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2. |
Inclusion Criteria: 1. Documented diagnosis of diabetes mellitus (Type 1 or Type 2) 2. Hemoglobin A1c of less than or equal to 12% 3. For women of childbearing potential: agreement to use acceptable contraceptive methods during the treatment period and for at least 90 days after the final dose of s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
ASKG712 is an investigational monoclonal antibody being developed for neovascular age-related macular degeneration and diabetic macular edema, both of which are conditions affecting the retina and central vision. It is currently in Phase 1 clinical development.
ASKG712 is being developed by NovaBridge Biosciences, a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol NBP.
ASKG712 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 studies have been completed, one in neovascular age-related macular degeneration and one in diabetic macular edema.
ASKG712 has been studied in two completed Phase 1 trials. The first, NCT05456828, enrolled 56 patients with neovascular age-related macular degeneration in China. The second, NCT05940428, enrolled 10 patients with diabetic macular edema in China.
Yes, ASKG712 is a monoclonal antibody. It is being developed as a treatment for neovascular age-related macular degeneration and diabetic macular edema, two common causes of vision loss.